Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.

Journal of the American Heart Association
William L BakerDave L Dixon

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycemic agents that improve glycemic control by increasing glycosuria. Additional benefits beyond glucose lowering include significant improvements in seated clinic blood pressure (BP), partly attributed to their diuretic-like actions. Less known are the effects of this class on 24-hour ambulatory BP, which is a better predictor of cardiovascular risk than seated clinic BP. We performed a meta-analysis of randomized, double-blind, placebo-controlled trials to investigate the effects of SGLT2 inhibitors on 24-hour ambulatory BP. We searched all studies published before August 17, 2016, which reported 24-hour ambulatory BP data. Mean differences in 24-hour BP, daytime BP, and nighttime BP were calculated by a random-effects model. SGLT2 inhibitors significantly reduce 24-hour ambulatory systolic and diastolic BP by -3.76 mm Hg (95% CI, -4.23 to -2.34; I2=0.99) and -1.83 mm Hg (95% CI, -2.35 to -1.31; I2=0.76), respectively. Significant reductions in daytime and nighttime systolic and diastolic BP were also found. No association between baseline BP or change in body weight were observed. This meta-analysis shows that the reduction in 24-hour ambulator...Continue Reading

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Jun 25, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·M G WulffeléC D A Stehouwer
Aug 10, 2007·American Journal of Physiology. Renal Physiology·Swasti TiwariCarolyn A Ecelbarger
Mar 13, 2013·Hypertension·Stanley S FranklinUNKNOWN International Database on Ambulatory blood pressure in Relation to Cardiovascular Outcomes Investigators
May 15, 2013·Diabetes, Obesity & Metabolism·H J Lambers HeerspinkJ List
Mar 8, 2014·Journal of the American Society of Hypertension : JASH·William L BakerWilliam B White
Oct 2, 2014·Diabetes Care·Ilkka TikkanenUNKNOWN EMPA-REG BP Investigators
Dec 4, 2014·Current Opinion in Nephrology and Hypertension·Marko Škrtić, David Z I Cherney
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 5, 2016·Cardiovascular Diabetology·Gianluca Perseghin, Anna Solini
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Dec 13, 2016·Nature Reviews. Nephrology·Ralph A DeFronzoMuhammad Abdul-Ghani

❮ Previous
Next ❯

Citations

Feb 20, 2018·The Journal of Clinical Hypertension·Kazuomi KarioEle Ferrannini
Aug 23, 2017·Expert Review of Clinical Pharmacology·Konstantinos P ImprialosVasilios G Athyros
Oct 31, 2018·Advances in Therapy·Jennifer OkemahManuel Quiñones
Sep 27, 2018·Annual Review of Medicine·Caroline K Kramer, Bernard Zinman
Feb 13, 2019·Current Hypertension Reports·Hillel Sternlicht, George L Bakris
Jan 20, 2018·Current Cardiology Reports·Alexandros BriasoulisGeorge L Bakris
Apr 18, 2020·Expert Opinion on Pharmacotherapy·Lakshini Y HeratMarkus P Schlaich
Sep 15, 2020·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki KayanoToshiro Shinke
Jul 12, 2018·Cardiovascular Diabetology·Sarayut LahnwongNipon Chattipakorn
Dec 4, 2019·Wiener klinische Wochenschrift·Thomas WeberUNKNOWN Österreichische Gesellschaft für Kinder- und Jugendheilkunde
Dec 10, 2019·European Heart Journal. Cardiovascular Pharmacotherapy·Susanne JungRoland E Schmieder
Jan 3, 2020·Journal of Primary Care & Community Health·Lea El HagePratibha Rao
Jun 28, 2020·Cardiovascular Diabetology·Lihua NiXiaoyan Wu
Aug 21, 2019·International Journal of Environmental Research and Public Health·Anastasios TentolourisNikolaos Tentolouris
Sep 22, 2019·American Journal of Hypertension·Elias A SanidasJohn Barbetseas
Jul 24, 2020·Indian Journal of Endocrinology and Metabolism·Rajeev ChawlaUNKNOWN RSSDI-ESI Consensus Group
Jan 8, 2019·Expert Opinion on Pharmacotherapy·Caroline A AndrewLouis J Aronne
Feb 1, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·David Z CherneyJulie A Lovshin
Aug 17, 2020·The Journal of Biological Chemistry·Rachel J Perry, Gerald I Shulman
Nov 27, 2020·Journal of Cardiovascular Translational Research·Ruju Vashi, Bhoomika M Patel
Nov 10, 2020·Journal of Cardiovascular Pharmacology·Thomas D Bernier, Leo F Buckley
Sep 26, 2020·American Journal of Hypertension·Karen C Tran, Swapnil Hiremath
Mar 25, 2021·Acta Diabetologica·Giovanna CastoldiCira R T di Gioia
Jun 2, 2021·Current Opinion in Cardiology·Muhannad AlqudsiJose Navarrete
Jun 4, 2021·Current Cardiology Reports·Tina K ThethiRichard E Pratley
Jun 3, 2021·International Journal of Molecular Sciences·Giuseppe PalmieroFerdinando Carlo Sasso
May 22, 2021·Lancet·Sofie BrouwersElisabeth M Sulaica
Jul 23, 2021·Expert Opinion on Pharmacotherapy·Omar AzzamMarkus P Schlaich
Aug 4, 2021·Aging and Disease·Le LiuYou-Shuo Liu
Jul 7, 2021·Hypertension·Kazuomi Kario, Bryan Williams

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01032629
NCT01730534

Software Mentioned

R
R Project for Statistical Computing

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.